Cargando…

Curcumin-Gene Expression Response in Hormone Dependent and Independent Metastatic Prostate Cancer Cells

The androgen receptor is one of the key targets for prostate cancer treatment. Despite its less satisfactory effects, chemotherapy is the most common treatment option for metastatic and/or castration-resistant patients. There are constant needs for novel anti-prostate cancer therapeutic/prevention a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Katta, Shilpa, Srivastava, Arun, Thangapazham, Rajesh L., Rosner, Inger L., Cullen, Jennifer, Li, Hua, Sharad, Shashwat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6801832/ https://www.ncbi.nlm.nih.gov/pubmed/31581661 http://dx.doi.org/10.3390/ijms20194891

Ejemplares similares

Characterization of unique PMEPA1 gene splice variants (isoforms d and e) from RNA Seq profiling provides novel insights into prognostic evaluation of prostate cancer
por: Sharad, Shashwat, et al.
Publicado: (2020)

Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer
por: Thangapazham, Rajesh, et al.
Publicado: (2014)

Analysis of PMEPA1 Isoforms (a and b) as Selective Inhibitors of Androgen and TGF-β Signaling Reveals Distinct Biological and Prognostic Features in Prostate Cancer
por: Sharad, Shashwat, et al.
Publicado: (2019)

PMEPA1 Gene Isoforms: A Potential Biomarker and Therapeutic Target in Prostate Cancer
por: Sharad, Shashwat, et al.
Publicado: (2020)

Editorial: Identification of therapeutic targets and novel biomarkers in prostate cancer volume II
por: Sharad, Shashwat, et al.
Publicado: (2023)

Mechanism of Anti-Cancer Activity of Curcumin on Androgen-Dependent and Androgen-Independent Prostate Cancer
por: Abd. Wahab, Nurul Azwa, et al.
Publicado: (2020)

Prostate cancer gene expression signature of patients with high body mass index
por: Sharad, Shashwat, et al.
Publicado: (2010)

Molecular profiling of radical prostatectomy tissue from patients with no sign of progression identifies ERG as the strongest independent predictor of recurrence
por: Yan, Wusheng, et al.
Publicado: (2019)

Loss of miR-449a in ERG-associated prostate cancer promotes the invasive phenotype by inducing SIRT1
por: Kumar, Parameet, et al.
Publicado: (2016)

Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer
por: Chen, Kenneth, et al.
Publicado: (2022)

Age and Tumor Differentiation-Associated Gene Expression Based Analysis of Non-Familial Prostate Cancers
por: Sharad, Shashwat, et al.
Publicado: (2021)

Focal p53 protein expression and lymphovascular invasion in primary prostate tumors predict metastatic progression
por: Gesztes, William, et al.
Publicado: (2022)

Curcumin: Modulator of Key Molecular Signaling Pathways in Hormone-Independent Breast Cancer
por: Farghadani, Reyhaneh, et al.
Publicado: (2021)

ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development
por: Sreenath, Taduru L., et al.
Publicado: (2017)

Alteration of Skin Properties with Autologous Dermal Fibroblasts
por: Thangapazham, Rajesh L., et al.
Publicado: (2014)

Hormonal Intensification Should Start at the Low-risk Stage in Metastatic Prostate Cancer
por: Jazayeri, Seyed Behzad, et al.
Publicado: (2022)

Erratum: ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development
por: Sreenath, Taduru L., et al.
Publicado: (2017)

Differential Effects of Leptin on the Invasive Potential of Androgen-Dependent and -Independent Prostate Carcinoma Cells
por: Deo, Dayanand D., et al.
Publicado: (2008)

Association of germline genetic variants with TMPRSS2-ERG fusion status in prostate cancer
por: Kohaar, Indu, et al.
Publicado: (2020)

The Curcumin Derivative, H10, Suppresses Hormone-Dependent Prostate Cancer by Inhibiting 17β-Hydroxysteroid Dehydrogenase Type 3
por: Cheng, Yating, et al.
Publicado: (2020)

Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
por: Armstrong, Andrew J., et al.
Publicado: (2022)

Prostate radiotherapy for metastatic hormone sensitive prostate cancer—myth or reality?
por: Onal, Cem
Publicado: (2019)

Satraplatin in the treatment of hormone-refractory metastatic prostate cancer
por: Armstrong, Andrew J, et al.
Publicado: (2007)

Advancements in the treatment of metastatic hormone-sensitive prostate cancer
por: Li, Hengping, et al.
Publicado: (2022)

Alkaline Phosphatase Kinetics Predict Metastasis among Prostate Cancer Patients Who Experience Relapse following Radical Prostatectomy
por: Salter, Carolyn A., et al.
Publicado: (2018)

Intermittent chemotherapy in metastatic androgen-independent prostate cancer
por: Beer, T M, et al.
Publicado: (2003)

The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer.
por: Fosså, S. D., et al.
Publicado: (1992)

Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN
por: Li, Hua, et al.
Publicado: (2015)

Current treatment options for newly diagnosed metastatic hormone-sensitive prostate cancer—a narrative review
por: Ong, Sean, et al.
Publicado: (2021)

Development of an immunotherapeutic adenovirus targeting hormone-independent prostate cancer
por: Kim, Jae Sik, et al.
Publicado: (2013)

Indian Herb-Derived Phytoconstituent-Based Antiviral, Antimicrobial and Antifungal Formulation: An Oral Rinse Candidate for Oral Hygiene and the Potential Prevention of COVID-19 Outbreaks
por: Sharad, Shashwat, et al.
Publicado: (2021)

Aryl Hydrocarbon Receptor-Dependent and -Independent Pathways Mediate Curcumin Anti-Aging Effects
por: Brinkmann, Vanessa, et al.
Publicado: (2022)

Vitamin K2, a Naturally Occurring Menaquinone, Exerts Therapeutic Effects on Both Hormone-Dependent and Hormone-Independent Prostate Cancer Cells
por: Samykutty, Abhilash, et al.
Publicado: (2013)

Hormonal Therapy in Metastatic Prostate Cancer: Current Perspectives and Controversies
por: Garg, Manish, et al.
Publicado: (2013)

Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer
por: Shenoy, Niraj, et al.
Publicado: (2016)

Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer
por: Cattrini, Carlo, et al.
Publicado: (2019)

Metastatic hormone-sensitive prostate cancer: How should it be treated?
por: López-Campos, Fernando, et al.
Publicado: (2021)

Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
por: Lee, Arnold
Publicado: (2023)

Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone.
por: Jungwirth, A., et al.
Publicado: (1997)

Metastatic Hormone-sensitive Prostate Cancer: Current Perspective on the Evolving Therapeutic Landscape
por: Hall, Mary E, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1bgqfgk35mfegudfi9gt5knodv